- Sangamo Therapeutics, Inc.
- Global Blood Therapeutics, Inc.
- Bluebird bio, Inc.
- Emmaus Life Sciences Inc.
- Pfizer, Inc.
- Novartis AG
- Prolong Pharmaceuticals, LLC
- Bioverativ Inc.
- Gamida Cell
- Alnylam Pharmaceuticals
- Biogen Idec
- AcceleronPharma
- Anthera Pharmaceuticals
- Genetix Pharmaceuticals
- Mast Therapeutics
- Calgene Corporation
(Note: The list of the major players will be updated with the latest market scenario and trends)
Recent developments by key players in Hemoglobinopathies Market:
In January 2022, Sanofi stated that it would transfer its rights and responsibilities for SAR445136, a zinc finger nuclease gene-edited cell therapy for the treatment of sickle cell disease, to Sangamo Therapeutics, Inc. (SCD). The worldwide research, development, and commercialization partnership and licensing agreement between the Companies to develop genetic treatments for hemoglobinopathies was terminated by Sanofi for administrative reasons prior to this change.
The global hemoglobinopathies market is driven by a variety of factors, including the high prevalence of various disorders, increasing awareness and screening efforts, and the development of new treatment options. One major driver of the market is the high prevalence of hemoglobinopathies, particularly sickle cell disease and thalassemia. According to the World Health Organization, sickle cell disease affects millions of people worldwide, with the majority living in sub-Saharan Africa. Thalassemia is also prevalent in this region, as well as in certain areas of Asia and the Mediterranean. In addition to the high prevalence of hemoglobinopathies, there has been increasing awareness and screening efforts in many regions. Governments, healthcare organizations, and advocacy groups have been working to raise awareness about these disorders and improve screening efforts, particularly in areas with high prevalence rates. The development of new treatment options is also driving the hemoglobinopathies market. In recent years, there have been many new therapies approved for the treatment of sickle cell disease, including gene therapies, gene editing technologies, and small-molecule drugs. Additionally, there are several promising treatments in development for thalassemia, including gene therapies and gene editing technologies.
Despite these positive drivers, the hemoglobinopathies market still faces a number of obstacles. These include the high cost of treatment, particularly for new and innovative therapies, as well as limited access to care and treatment in certain regions. Additionally, there is still much to learn about the underlying biology of these disorders, which could impact the development of new therapies and treatment approaches.